SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.
Authors
- Ignacio A. Romero (ORCID: https://orcid.org/0000-0002-0322-9180)
- Purificación Estévez-García
- Avinash Ramchandani-Vaswani
- María Quindós
- Luisa Sánchez‐Lorenzo (ORCID: https://orcid.org/0000-0001-9139-6730)
- Luís Manso (ORCID: https://orcid.org/0000-0002-1683-550X)
- Marta Gil-Martín (ORCID: https://orcid.org/0000-0002-8548-5355)
- Yolanda García García (ORCID: https://orcid.org/0000-0002-0280-4382)
- María José Bermejo-Pérez
- Lorena Fariña-Madrid
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital Universitario Insular de Gran Canaria (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Institut Català d'Oncologia (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Clinica Universidad de Navarra (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Instituto de Investigación Biomédica de A Coruña (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1007/s12094-024-03604-3
- Citations
- 15
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.74